Evidence map›Paper›PMID 39273149›Full record

ReviewInternational journal of molecular sciences2024

Development and Prospects of Furin Inhibitors for Therapeutic Applications.

Alexandre V Ivachtchenko, Alexander V Khvat, Dmitrii O Shkil

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Repurposing of Furin Inhibitors to Reduce PathogenicAntibiotics (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexandre V IvachtchenkoChemDiv Inc., San Diego, CA 92130, USA.
Alexander V KhvatChemDiv Inc., San Diego, CA 92130, USA.
Dmitrii O ShkilChemDiv Inc., San Diego, CA 92130, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Furin, a serine protease enzyme located in the Golgi apparatus of animal cells, plays a crucial role in cleaving precursor proteins into their mature, active forms. It is ubiquitously expressed across various tissues, including the brain, lungs, gastrointestinal tract, liver, pancreas, and reproductive organs. Since its discovery in 1990, furin has been recognized as a significant therapeutic target, leading to the active development of furin inhibitors for potential use in antiviral, antibacterial, anticancer, and other therapeutic applications. This review provides a comprehensive overview of the progress in the development and characterization of furin inhibitors, encompassing peptides, linear and macrocyclic peptidomimetics, and non-peptide compounds, highlighting their potential in the treatment of both infectious and non-infectious diseases.

Indexed as

FurinAnimalsAntineoplastic AgentsAntiviral AgentsDrug DevelopmentHumansPeptidesPeptidomimeticsAntineoplastic AgentsAntiviral AgentsFurinPeptidesPeptidomimeticsbacterial toxinscancersCOVID-19furininfluenzaPACEpan-protease inhibitorPC1PC1/3PC3PCSK3proprotein convertase (PC)SARS-CoV-2serine protease inhibitorviral proteins HIV

Identifiers

PMID39273149
PMCPMC11394684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.